Minerva Surgical, Inc. (NASDAQ:UTRS – Get Free Report)’s share price fell 8.9% during mid-day trading on Wednesday . The company traded as low as $0.51 and last traded at $0.51. 600 shares were traded during trading, a decline of 84% from the average session volume of 3,772 shares. The stock had previously closed at $0.56.
Minerva Surgical Stock Performance
The company has a market capitalization of $4.53 million, a price-to-earnings ratio of -0.06 and a beta of 0.67. The company has a current ratio of 1.88, a quick ratio of 1.03 and a debt-to-equity ratio of 1.38. The stock’s fifty day simple moving average is $0.62 and its 200-day simple moving average is $1.48.
Institutional Investors Weigh In On Minerva Surgical
A number of hedge funds and other institutional investors have recently modified their holdings of UTRS. Vanguard Group Inc. raised its holdings in shares of Minerva Surgical by 64.8% in the 1st quarter. Vanguard Group Inc. now owns 378,781 shares of the company’s stock valued at $1,705,000 after purchasing an additional 148,915 shares in the last quarter. State Street Corp raised its holdings in shares of Minerva Surgical by 950.6% in the 2nd quarter. State Street Corp now owns 161,800 shares of the company’s stock valued at $41,000 after purchasing an additional 146,400 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Minerva Surgical by 284.7% in the 2nd quarter. Geode Capital Management LLC now owns 128,749 shares of the company’s stock valued at $33,000 after purchasing an additional 95,284 shares in the last quarter.
Minerva Surgical Company Profile
Minerva Surgical, Inc, a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company provides Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps.
See Also
- Five stocks we like better than Minerva Surgical
- Business Services Stocks Investing
- United Airlines Soars on Earnings Beat
- What are earnings reports?
- J.B. Hunt Hits the Skids: Lower Prices to Come
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Minerva Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Surgical and related companies with MarketBeat.com's FREE daily email newsletter.
